$SLS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SELLAS Life Sciences Group, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SELLAS Life Sciences Group, Inc.. Get notifications about new insider transactions in SELLAS Life Sciences Group, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 09 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Sell | S | 5.92 | 150,000 | 888,540 | 5,000 | 155 K to 5 K (-96.77 %) |
Apr 09 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Buy | M | 2.31 | 50,000 | 115,500 | 155,000 | 105 K to 155 K (+47.62 %) |
Apr 09 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Buy | M | 1.18 | 100,000 | 118,000 | 105,000 | 5 K to 105 K (+2,000.00 %) |
Feb 13 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | P | 4.94 | 20,000 | 98,742 | 23,500 | 3.5 K to 23.5 K (+571.43 %) |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | M | 1.71 | 37,500 | 64,125 | 12,500 | |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | M | 2.31 | 50,000 | 115,500 | 0 | |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Sell | S | 4.33 | 187,500 | 812,438 | 0 | 187.5 K to 0 (-100.00 %) |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Buy | M | 1.71 | 37,500 | 64,125 | 187,500 | 150 K to 187.5 K (+25.00 %) |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Buy | M | 1.18 | 100,000 | 118,000 | 150,000 | 50 K to 150 K (+200.00 %) |
Feb 13 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Buy | M | 2.31 | 50,000 | 115,500 | 50,000 | 0 to 50 K |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | M | 1.71 | 50,000 | 85,500 | 0 | |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | M | 0.72 | 50,000 | 36,000 | 0 | |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | M | 0.85 | 50,000 | 42,500 | 0 | |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | M | 2.31 | 50,000 | 115,500 | 0 | |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Sell | S | 4.18 | 300,000 | 1,253,040 | 10,000 | 310 K to 10 K (-96.77 %) |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Buy | M | 1.71 | 50,000 | 85,500 | 310,000 | 260 K to 310 K (+19.23 %) |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Buy | M | 0.72 | 50,000 | 36,000 | 260,000 | 210 K to 260 K (+23.81 %) |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Buy | M | 0.85 | 50,000 | 42,500 | 210,000 | 160 K to 210 K (+31.25 %) |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Buy | M | 1.18 | 100,000 | 118,000 | 160,000 | 60 K to 160 K (+166.67 %) |
Feb 05 2014 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Buy | M | 2.31 | 50,000 | 115,500 | 60,000 | 10 K to 60 K (+500.00 %) |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | M | 0.85 | 25,000 | 21,250 | 0 | |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | M | 0.72 | 50,000 | 36,000 | 0 | |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Sell | S | 5.61 | 25,000 | 140,255 | 0 | 25 K to 0 (-100.00 %) |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Sell | S | 5.57 | 50,000 | 278,500 | 25,000 | 75 K to 25 K (-66.67 %) |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Buy | M | 0.85 | 25,000 | 21,250 | 75,000 | 50 K to 75 K (+50.00 %) |
Feb 03 2014 | GALE | Galena Biopharma, ... | Chin Richard | Director | Buy | M | 0.72 | 50,000 | 36,000 | 50,000 | 0 to 50 K |
Jan 31 2014 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP & Chief Operati ... | Sell | S | 5.57 | 100,000 | 556,500 | 409,665 | 509.7 K to 409.7 K (-19.62 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | H | 1.71 | 50,000 | 85,500 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Gift | G | 0.00 | 15,000 | 0 | 95,447 | 110.4 K to 95.4 K (-13.58 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Sell | S | 5.41 | 250,000 | 1,352,500 | 17,974 | 268 K to 18 K (-93.29 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Buy | M | 1.71 | 50,000 | 85,500 | 267,974 | 218 K to 268 K (+22.94 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Buy | M | 1.18 | 200,000 | 236,000 | 217,974 | 18 K to 218 K (+1,112.72 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 1.71 | 50,000 | 85,500 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 0.72 | 50,000 | 36,000 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 2.31 | 50,000 | 115,500 | 0 | |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Sell | S | 5.28 | 250,000 | 1,320,000 | 3,500 | 253.5 K to 3.5 K (-98.62 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 1.71 | 50,000 | 85,500 | 253,500 | 203.5 K to 253.5 K (+24.57 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 0.72 | 50,000 | 36,000 | 203,500 | 153.5 K to 203.5 K (+32.57 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 1.18 | 100,000 | 118,000 | 153,500 | 53.5 K to 153.5 K (+186.92 %) |
Jan 31 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 2.31 | 50,000 | 115,500 | 53,500 | 3.5 K to 53.5 K (+1,428.57 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | M | 1.71 | 121,875 | 208,406 | 423,173 | |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | M | 0.72 | 200,000 | 144,000 | 200,000 | |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | M | 1.38 | 324,890 | 448,348 | 25,110 | |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | M | 1.38 | 100,000 | 138,000 | 0 | |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | M | 2.31 | 50,000 | 115,500 | 0 | |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Sell | S | 4.83 | 796,765 | 3,848,375 | 113,764 | 910.5 K to 113.8 K (-87.51 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | M | 1.71 | 121,875 | 208,406 | 918,529 | 796.7 K to 918.5 K (+15.30 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | M | 0.72 | 200,000 | 144,000 | 788,654 | 588.7 K to 788.7 K (+33.98 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | M | 1.38 | 324,890 | 448,348 | 588,654 | 263.8 K to 588.7 K (+123.17 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | M | 1.38 | 100,000 | 138,000 | 263,764 | 163.8 K to 263.8 K (+61.06 %) |
Jan 29 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | M | 2.31 | 50,000 | 115,500 | 163,764 | 113.8 K to 163.8 K (+43.95 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | J | 1.88 | 5,656 | 10,625 | 113,764 | 108.1 K to 113.8 K (+5.23 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP & Chief Operati ... | Buy | J | 1.88 | 5,656 | 10,625 | 509,665 | 504 K to 509.7 K (+1.12 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Dunlap Ryan | Principal Accountin ... | Buy | J | 1.88 | 2,728 | 5,125 | 5,343 | 2.6 K to 5.3 K (+104.32 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Sell | S | 6.93 | 200,000 | 1,385,000 | 110,447 | 310.4 K to 110.4 K (-64.42 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | M | 0.72 | 50,000 | 36,000 | 0 | |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | M | 1.18 | 200,000 | 236,000 | 0 | |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | M | 0.85 | 200,000 | 170,000 | 0 | |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Sell | S | 6.13 | 250,000 | 1,532,500 | 5,000 | 255 K to 5 K (-98.04 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Buy | M | 0.72 | 50,000 | 36,000 | 255,000 | 205 K to 255 K (+24.39 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Buy | M | 1.18 | 200,000 | 236,000 | 205,000 | 5 K to 205 K (+4,000.00 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Sell | S | 7.00 | 200,000 | 1,400,000 | 5,000 | 205 K to 5 K (-97.56 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Buy | M | 0.85 | 200,000 | 170,000 | 205,000 | 5 K to 205 K (+4,000.00 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 0.85 | 100,000 | 85,000 | 0 | |
Jan 22 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | M | 1.18 | 100,000 | 118,000 | 0 | |
Jan 22 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Sell | S | 6.90 | 200,000 | 1,380,000 | 3,500 | 203.5 K to 3.5 K (-98.28 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 0.85 | 100,000 | 85,000 | 203,500 | 103.5 K to 203.5 K (+96.62 %) |
Jan 22 2014 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Buy | M | 1.18 | 100,000 | 118,000 | 103,500 | 3.5 K to 103.5 K (+2,857.14 %) |
Jan 16 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | M | 0.85 | 200,000 | 170,000 | 0 | |
Jan 16 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Payment of Exercise | F | 6.96 | 24,426 | 170,005 | 310,447 | 334.9 K to 310.4 K (-7.29 %) |
Jan 16 2014 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Buy | M | 0.85 | 200,000 | 170,000 | 334,873 | 134.9 K to 334.9 K (+148.29 %) |
Dec 16 2013 | GALE | Galena Biopharma, ... | HAMILTON BRIAN L | EVP & Chief Medical ... | Option Exercise | A | 3.88 | 300,000 | 1,164,000 | 300,000 | |
Dec 13 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | M | 0.72 | 50,000 | 36,000 | 0 | |
Dec 13 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Payment of Exercise | F | 4.19 | 8,592 | 36,000 | 134,873 | 143.5 K to 134.9 K (-5.99 %) |
Dec 13 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Buy | M | 0.72 | 50,000 | 36,000 | 143,375 | 93.4 K to 143.4 K (+53.55 %) |
Dec 13 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Gift | G | 0.00 | 37,001 | 0 | 93,375 | 130.4 K to 93.4 K (-28.38 %) |
Nov 27 2013 | GALE | Galena Biopharma, ... | Ashton William | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Dunlap Ryan | Chief Accounting Of ... | Option Exercise | A | 3.88 | 150,000 | 582,000 | 150,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | Chief Operating Off ... | Option Exercise | A | 3.88 | 300,000 | 1,164,000 | 300,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Ahn Mark J | President and CEO | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Ahn Mark J | President and CEO | Option Exercise | A | 3.88 | 600,000 | 2,328,000 | 600,000 | |
Nov 27 2013 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | A | 3.88 | 200,000 | 776,000 | 200,000 | |
Oct 15 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 2,630 | 0 | 17,974 | 15.3 K to 18 K (+17.14 %) |
Oct 15 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP, Chief Operatin ... | Grant | A | 0.00 | 7,349 | 0 | 504,009 | 496.7 K to 504 K (+1.48 %) |
Jul 03 2013 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | J | 1.35 | 7,862 | 10,614 | 108,108 | 100.2 K to 108.1 K (+7.84 %) |
Jul 03 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP, Chief Operatin ... | Buy | J | 1.35 | 7,862 | 10,614 | 496,660 | 488.8 K to 496.7 K (+1.61 %) |
Jul 03 2013 | GALE | Galena Biopharma, ... | Dunlap Ryan | Principal Accountin ... | Buy | J | 1.35 | 1,369 | 1,848 | 2,615 | 1.2 K to 2.6 K (+109.87 %) |
Jun 17 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP, Chief Operatin ... | Grant | A | 0.00 | 26,110 | 0 | 488,798 | 462.7 K to 488.8 K (+5.64 %) |
Jun 13 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 9,327 | 0 | 145,703 | 136.4 K to 145.7 K (+6.84 %) |
May 02 2013 | GALE | Galena Biopharma, ... | Galena Biopharma, Inc. | 10% Owner | Sell | S | 0.19 | 253,000 | 48,197 | 32,393,095 | 32.6 M to 32.4 M (-0.77 %) |
May 02 2013 | GALE | Galena Biopharma, ... | Galena Biopharma, Inc. | 10% Owner | Sell | S | 0.19 | 659,500 | 126,954 | 32,646,095 | 33.3 M to 32.6 M (-1.98 %) |
May 02 2013 | GALE | Galena Biopharma, ... | Galena Biopharma, Inc. | 10% Owner | Sell | S | 0.21 | 171,000 | 36,560 | 33,305,595 | 33.5 M to 33.3 M (-0.51 %) |
Apr 30 2013 | GALE | Galena Biopharma, ... | Ashton William | Director | Option Exercise | A | 2.54 | 100,000 | 254,000 | 100,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | A | 1.71 | 650,000 | 1,111,500 | 650,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | J | 1.30 | 7,668 | 9,968 | 100,246 | 92.6 K to 100.2 K (+8.28 %) |
Jan 31 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP, Chief Operatin ... | Option Exercise | A | 1.71 | 250,000 | 427,500 | 250,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP, Chief Operatin ... | Buy | J | 1.30 | 7,668 | 9,968 | 462,688 | 455 K to 462.7 K (+1.69 %) |
Jan 31 2013 | GALE | Galena Biopharma, ... | MAZANET ROSEMARY | Chief Medical Offic ... | Option Exercise | A | 1.71 | 450,000 | 769,500 | 450,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Dunlap Ryan | Principal Accountin ... | Option Exercise | A | 1.71 | 40,000 | 68,400 | 40,000 | |
Jan 31 2013 | GALE | Galena Biopharma, ... | Dunlap Ryan | Principal Accountin ... | Buy | J | 1.30 | 1,246 | 1,620 | 1,246 | 0 to 1.2 K |
Nov 05 2012 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Gift | G | 0.00 | 20,000 | 0 | 136,376 | 156.4 K to 136.4 K (-12.79 %) |
Jul 11 2012 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operating ... | Buy | J | 0.40 | 21,902 | 8,750 | 461,809 | 439.9 K to 461.8 K (+4.98 %) |
Jul 11 2012 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operating ... | Grant | A | 0.00 | 89,322 | 0 | 439,907 | 350.6 K to 439.9 K (+25.48 %) |
Jul 11 2012 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | J | 0.40 | 31,289 | 12,500 | 92,578 | 61.3 K to 92.6 K (+51.05 %) |
Jul 10 2012 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 31,966 | 0 | 156,376 | 124.4 K to 156.4 K (+25.69 %) |
Jun 19 2012 | GALE | Galena Biopharma, ... | MAZANET ROSEMARY | Chief Medical Offic ... | Option Exercise | A | 1.73 | 150,000 | 259,500 | 150,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | A | 0.72 | 50,000 | 36,000 | 50,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | A | 0.72 | 50,000 | 36,000 | 50,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | A | 0.72 | 50,000 | 36,000 | 50,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | A | 0.72 | 50,000 | 36,000 | 50,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | A | 0.72 | 50,000 | 36,000 | 50,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operating ... | Option Exercise | A | 0.72 | 200,000 | 144,000 | 200,000 | |
Jan 17 2012 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Option Exercise | A | 0.72 | 400,000 | 288,000 | 400,000 | |
Jan 09 2012 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operating ... | Buy | J | 0.40 | 12,924 | 5,170 | 350,585 | 337.7 K to 350.6 K (+3.83 %) |
Jan 06 2012 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | J | 0.40 | 31,289 | 12,516 | 61,289 | 30 K to 61.3 K (+104.30 %) |
Dec 07 2011 | GALE | Galena Biopharma, ... | Lee Kwang | Principal Accountin ... | Buy | P | 0.60 | 5,000 | 3,000 | 5,000 | 0 to 5 K |
Dec 07 2011 | GALE | Galena Biopharma, ... | Ahn Mark J | President & CEO | Buy | P | 0.66 | 10,000 | 6,590 | 20,000 | 10 K to 20 K (+100.00 %) |
Sep 29 2011 | GALE | Galena Biopharma, ... | GALLIKER STEPHEN S | Director | Option Exercise | A | 0.85 | 50,000 | 42,500 | 50,000 | |
Sep 29 2011 | GALE | Galena Biopharma, ... | Chin Richard | Director | Option Exercise | A | 0.85 | 25,000 | 21,250 | 25,000 | |
Sep 29 2011 | GALE | Galena Biopharma, ... | KRIEGSMAN STEVEN A | Director | Option Exercise | A | 0.85 | 200,000 | 170,000 | 200,000 | |
Sep 28 2011 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Option Exercise | A | 0.85 | 200,000 | 170,000 | 200,000 | |
Sep 28 2011 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | A | 0.85 | 100,000 | 85,000 | 100,000 | |
Sep 27 2011 | GALE | Galena Biopharma, ... | Pavco Pamela | Option Exercise | A | 0.65 | 150,000 | 97,500 | 150,000 | ||
Sep 27 2011 | GALE | Galena Biopharma, ... | Khvorova Anastasia | Grant | A | 0.00 | 76,923 | 0 | 137,482 | 60.6 K to 137.5 K (+127.02 %) | |
Sep 26 2011 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operating ... | Option Exercise | A | 1.00 | 250,000 | 250,000 | 250,000 | |
Apr 21 2011 | GALE | Galena Biopharma, ... | Ahn Mark J | President and CEO | Option Exercise | A | 1.38 | 525,000 | 724,500 | 525,000 | |
Apr 21 2011 | GALE | Galena Biopharma, ... | Ahn Mark J | President and CEO | Option Exercise | A | 1.38 | 100,000 | 138,000 | 100,000 | |
Apr 22 2011 | GALE | Galena Biopharma, ... | Kennedy Robert Eugene | Vice President and ... | Option Exercise | A | 1.28 | 30,000 | 38,250 | 30,000 | |
Apr 22 2011 | GALE | Galena Biopharma, ... | Kennedy Robert Eugene | Vice President and ... | Grant | A | 0.00 | 2,576 | 0 | 379,294 | 376.7 K to 379.3 K (+0.68 %) |
Apr 22 2011 | GALE | Galena Biopharma, ... | Kennedy Robert Eugene | Vice President and ... | Grant | A | 0.00 | 2,430 | 0 | 376,718 | 374.3 K to 376.7 K (+0.65 %) |
Apr 22 2011 | GALE | Galena Biopharma, ... | Kennedy Robert Eugene | Vice President and ... | Grant | A | 0.00 | 374,288 | 0 | 374,288 | 0 to 374.3 K |
Apr 22 2011 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operatin ... | Option Exercise | A | 1.28 | 40,000 | 51,000 | 40,000 | |
Apr 22 2011 | GALE | Galena Biopharma, ... | SCHWARTZ MARK W. | EVP Chief Operatin ... | Grant | A | 0.00 | 337,661 | 0 | 337,661 | 0 to 337.7 K |
Apr 20 2011 | GALE | Galena Biopharma, ... | Ahn Mark J | President and CEO | Buy | P | 0.95 | 10,000 | 9,500 | 10,000 | 0 to 10 K |
Apr 15 2011 | GALE | Galena Biopharma, ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 135,159 | 0 | 141,159 | 6 K to 141.2 K (+2,252.65 %) |
Mar 29 2011 | GALE | Galena Biopharma, ... | Nisi Rudolph | Director | Option Exercise | A | 1.18 | 100,000 | 118,000 | 100,000 |